Cargando…

Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.

Mast cells were shown to accumulate around the periphery of the invasive and metastatic rat mammary adenocarcinoma (MTLn3), and histological evidence of mast cell degranulation was observed during the later stages of this model. To assess the physiological role of mast cells in vivo we have used the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabbous, M. K., Haney, L., Nicolson, G. L., Eckley, D., Woolley, D. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972547/
https://www.ncbi.nlm.nih.gov/pubmed/2069844
_version_ 1782135028453474304
author Dabbous, M. K.
Haney, L.
Nicolson, G. L.
Eckley, D.
Woolley, D. E.
author_facet Dabbous, M. K.
Haney, L.
Nicolson, G. L.
Eckley, D.
Woolley, D. E.
author_sort Dabbous, M. K.
collection PubMed
description Mast cells were shown to accumulate around the periphery of the invasive and metastatic rat mammary adenocarcinoma (MTLn3), and histological evidence of mast cell degranulation was observed during the later stages of this model. To assess the physiological role of mast cells in vivo we have used the mast cell-stabilising compound FPL 55618 applied i.p. daily at 1 mg kg-1 for 23 days. Using groups of 12 rats we have found that this compound inhibited tumour growth at the primary site by as much as 70% in most of the treated animals compared with the control group which received equivalent volumes of saline. When the drug treatment was stopped after 23 days, tumour growth of the test group accelerated over the next 7 days and reached a similar tumour size to that of control animals. Histological studies of the tumour and contiguous host tissue at day 24 of the experiment revealed numerous extra-tumoural mast cells often showing signs of degranulation at several sites around the tumour periphery in the control animals. Such observations were not seen in those animals receiving FPL 55618 where, in contrast to controls, numerous intact mast cells were often seen within the tumour mass. Following cessation of the MC-stabilising treatment progressive mast cell activation was evident within 2-4 days, primarily at the tumour periphery. In vitro studies have shown that drug concentrations equivalent to five times the in vivo dose had no effect on the proliferative rate or viability of the MTLn3 cells. Moreover, the proliferative rate of these cells in culture was significantly increased when exposed to soluble mast cell products. Thus our data indicate that a mast cell-stabilising compound has significant benefits in reducing tumour growth in vivo, an observation which supports the concept that mast cell:tumour cell interactions are important for the growth and invasive properties demonstrated by this model of breast carcinoma. IMAGES:
format Text
id pubmed-1972547
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19725472009-09-10 Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Dabbous, M. K. Haney, L. Nicolson, G. L. Eckley, D. Woolley, D. E. Br J Cancer Research Article Mast cells were shown to accumulate around the periphery of the invasive and metastatic rat mammary adenocarcinoma (MTLn3), and histological evidence of mast cell degranulation was observed during the later stages of this model. To assess the physiological role of mast cells in vivo we have used the mast cell-stabilising compound FPL 55618 applied i.p. daily at 1 mg kg-1 for 23 days. Using groups of 12 rats we have found that this compound inhibited tumour growth at the primary site by as much as 70% in most of the treated animals compared with the control group which received equivalent volumes of saline. When the drug treatment was stopped after 23 days, tumour growth of the test group accelerated over the next 7 days and reached a similar tumour size to that of control animals. Histological studies of the tumour and contiguous host tissue at day 24 of the experiment revealed numerous extra-tumoural mast cells often showing signs of degranulation at several sites around the tumour periphery in the control animals. Such observations were not seen in those animals receiving FPL 55618 where, in contrast to controls, numerous intact mast cells were often seen within the tumour mass. Following cessation of the MC-stabilising treatment progressive mast cell activation was evident within 2-4 days, primarily at the tumour periphery. In vitro studies have shown that drug concentrations equivalent to five times the in vivo dose had no effect on the proliferative rate or viability of the MTLn3 cells. Moreover, the proliferative rate of these cells in culture was significantly increased when exposed to soluble mast cell products. Thus our data indicate that a mast cell-stabilising compound has significant benefits in reducing tumour growth in vivo, an observation which supports the concept that mast cell:tumour cell interactions are important for the growth and invasive properties demonstrated by this model of breast carcinoma. IMAGES: Nature Publishing Group 1991-06 /pmc/articles/PMC1972547/ /pubmed/2069844 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dabbous, M. K.
Haney, L.
Nicolson, G. L.
Eckley, D.
Woolley, D. E.
Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title_full Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title_fullStr Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title_full_unstemmed Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title_short Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF.
title_sort mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762nf.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972547/
https://www.ncbi.nlm.nih.gov/pubmed/2069844
work_keys_str_mv AT dabbousmk mastcellmodulationoftumourcellproliferationinratmammaryadenocarcinoma13762nf
AT haneyl mastcellmodulationoftumourcellproliferationinratmammaryadenocarcinoma13762nf
AT nicolsongl mastcellmodulationoftumourcellproliferationinratmammaryadenocarcinoma13762nf
AT eckleyd mastcellmodulationoftumourcellproliferationinratmammaryadenocarcinoma13762nf
AT woolleyde mastcellmodulationoftumourcellproliferationinratmammaryadenocarcinoma13762nf